Literature DB >> 21920055

Neonatal jaundice.

Paul Woodgate1, Luke Anthony Jardine.   

Abstract

INTRODUCTION: About 50% of term and 80% of preterm babies develop jaundice, which usually appears 2 to 4 days after birth, and resolves spontaneously after 1 to 2 weeks. Jaundice is caused by bilirubin deposition in the skin. Most jaundice in newborn infants is a result of increased red cell breakdown and decreased bilirubin excretion. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for unconjugated hyperbilirubinaemia in term and preterm infants? We searched Medline, Embase, The Cochrane Library, and other important databases up to February 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 42 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: albumin infusion, exchange transfusion, home phototherapy, immunoglobulin, hospital phototherapy, and tin-mesoporphyrin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920055      PMCID: PMC3217664     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  39 in total

1.  A new blue light-emitting phototherapy device: a prospective randomized controlled study.

Authors:  D S Seidman; J Moise; Z Ergaz; A Laor; H J Vreman; D K Stevenson; R Gale
Journal:  J Pediatr       Date:  2000-06       Impact factor: 4.406

Review 2.  An evidence-based review of important issues concerning neonatal hyperbilirubinemia.

Authors:  Stanley Ip; Mei Chung; John Kulig; Rebecca O'Brien; Robert Sege; Stephan Glicken; M Jeffrey Maisels; Joseph Lau
Journal:  Pediatrics       Date:  2004-07       Impact factor: 7.124

3.  A randomized trial of aggressive versus conservative phototherapy for hyperbilirubinemia in infants weighing less than 1500 g: Short- and long-term outcomes.

Authors:  Krista A Jangaard; Michael J Vincer; Alexander C Allen
Journal:  Paediatr Child Health       Date:  2007-12       Impact factor: 2.253

4.  Efficacy of phototherapy in prevention and management of neonatal hyperbilirubinemia.

Authors:  A K Brown; M H Kim; P Y Wu; D A Bryla
Journal:  Pediatrics       Date:  1985-02       Impact factor: 7.124

5.  Serum bilirubin kinetics in intermittent phototherapy of physiological jaundice.

Authors:  S P Lau; K P Fung
Journal:  Arch Dis Child       Date:  1984-09       Impact factor: 3.791

6.  Phototherapy for neonatal hyperbilirubinemia: six-year follow-up of the National Institute of Child Health and Human Development clinical trial.

Authors:  P C Scheidt; D A Bryla; K B Nelson; D G Hirtz; H J Hoffman
Journal:  Pediatrics       Date:  1990-04       Impact factor: 7.124

7.  Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn.

Authors:  A M Miqdad; O B Abdelbasit; M M Shaheed; M Z Seidahmed; A M Abomelha; O P Arcala
Journal:  J Matern Fetal Neonatal Med       Date:  2004-09

Review 8.  Kernicterus in term and near-term infants--the specter walks again.

Authors:  T W Hansen
Journal:  Acta Paediatr       Date:  2000-10       Impact factor: 2.299

9.  Therapeutic effect of turquoise versus blue light with equal irradiance in preterm infants with jaundice.

Authors:  Finn Ebbesen; Poul Madsen; Søren Støvring; Heidi Hundborg; Giovanni Agati
Journal:  Acta Paediatr       Date:  2007-06       Impact factor: 2.299

10.  Aggressive vs. conservative phototherapy for infants with extremely low birth weight.

Authors:  Brenda H Morris; William Oh; Jon E Tyson; David K Stevenson; Dale L Phelps; T Michael O'Shea; Georgia E McDavid; Rebecca L Perritt; Krisa P Van Meurs; Betty R Vohr; Cathy Grisby; Qing Yao; Claudia Pedroza; Abhik Das; W Kenneth Poole; Waldemar A Carlo; Shahnaz Duara; Abbot R Laptook; Walid A Salhab; Seetha Shankaran; Brenda B Poindexter; Avroy A Fanaroff; Michele C Walsh; Maynard R Rasmussen; Barbara J Stoll; C Michael Cotten; Edward F Donovan; Richard A Ehrenkranz; Ronnie Guillet; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

View more
  5 in total

Review 1.  Challenges in developing a consensus definition of neonatal sepsis.

Authors:  Matthew McGovern; Eric Giannoni; Helmut Kuester; Mark A Turner; Agnes van den Hoogen; Joseph M Bliss; Joyce M Koenig; Fleur M Keij; Jan Mazela; Rebecca Finnegan; Marina Degtyareva; Sinno H P Simons; Willem P de Boode; Tobias Strunk; Irwin K M Reiss; James L Wynn; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2020-03-03       Impact factor: 3.756

2.  Transcutaneous bilirubinometry during and after phototherapy in preterm infants: a prospective observational study.

Authors:  Ali Ahmed Raba; Anne O'Sullivan; Jan Miletin
Journal:  BMJ Paediatr Open       Date:  2020-07-16

3.  Efficacy of transcutaneous bilirubinometry as compared to serum bilirubin in preterm newborn during phototherapy.

Authors:  Sunil Gothwal; Neelam Singh; Sadasivam Sitaraman; Ramesh Choudhary; Kailash Kumar Meena; Ghan Shyam Bairwa; Mohan Bairwa; Amrit Jeevan
Journal:  Eur J Pediatr       Date:  2021-06-12       Impact factor: 3.183

4.  Prevalence and burden of illness of treated hemolytic neonatal hyperbilirubinemia in a privately insured population in the United States.

Authors:  Tzy-Chyi Yu; Chi Nguyen; Nancy Ruiz; Siting Zhou; Xian Zhang; Elaine A Böing; Hiangkiat Tan
Journal:  BMC Pediatr       Date:  2019-02-11       Impact factor: 2.125

5.  Rolling stones: an instructive case of neonatal cholestasis.

Authors:  Paige Killelea; Shruti Sakhuja; Jose Hernandez; M John Hicks; Sanjiv Harpavat
Journal:  BMC Pediatr       Date:  2022-09-04       Impact factor: 2.567

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.